A Phase 2 interventional study of 180 mg/kg Alpha1-PI and 90 mg/kg Alpha1-PI in Type 1 Diabetes Mellitus, sponsored by Grifols Therapeutics LLC. Terminated at 36 sites in United States. Open to participants aged 6 Years to 35 Years. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 413th largest by enrollment of the 1,242 interventional ones that give a count, is one of 57 that started in 2014, is one of 188 in phase 2, and was the 563rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 6 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 57 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with new onset Type 1 Diabetes Mellitus (T1DM). Currently enrolling ages 12-35 only. Once 25 patients are randomized and data is reviewed enrollment will be opened to the child cohort. The purpose of this study is to evaluate the safety and efficacy of four dosing regimens of human plasma-derived alpha1-PI in T1DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current use of injected insulin therapy and one positive result on testing for any of the following antibodies (If not currently on insulin therapy, must have positive result for at least two of the below antibodies):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
Biological: 180 mg/kg Alpha1-PI
90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
Biological: 90 mg/kg Alpha1-PI
Weekly infusions of placebo for 26 weeks.
Biological: Placebo
180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
Biological: 180 mg/kg Alpha1-PI
90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
Biological: 90 mg/kg Alpha1-PI
Weekly infusions of placebo for 13 weeks.
Biological: Placebo
Drug page: Alpha 1-Antitrypsin
Also known as: Alpha1-antitrypsin, Prolastin-C, Alpha1-Proteinase Inhibitor (human), Modified Process, Alpha-1 MP
Drug page: Alpha 1-Antitrypsin
Also known as: Alpha1-antitrypsin, Prolastin-C, Alpha1-Proteinase Inhibitor (human), Modified Process, Alpha-1 MP
Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC)
C-peptide concentration during MMTT with high protein energy drink. "Dose" for time frame refers to intake of high protein energy drink.
Time frame: Baseline, Week 52 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)
Change From Baseline for MMTT Stimulated C-peptide 2h AUC
Time frame: Baseline, Weeks 14, 27, 39, 69, 87, and 104 (pre-high protein drink and 15, 30, 60, 90, 120 minutes post-drink)
Change From Baseline for HbA1c Levels
Time frame: Baseline, Weeks 14, 27, 39, 52, 69, 87, and 104
Number of Subjects With Overall Severe Hypoglycemic Episodes
Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.
Time frame: 104 weeks
Change From Baseline for Mean Daily Insulin Dose Requirements
Time frame: Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104
Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime
For each visit, the mean daily glucose levels were calculated over the previous 3-7 days prior to the study visit from blood glucose levels recorded daily prior to meals and bedtime.
Time frame: Baseline, Weeks 2, 4, 14, 27, 39, 52, 69, 87, and 104
| Milestone | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Started | 15 | 16 | 15 | 15 | 15 |
| Completed | 5 | 8 | 6 | 7 | 7 |
| Not completed | 10 | 8 | 9 | 8 | 8 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 4 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Study termination | 6 | 5 | 4 | 6 | 7 |
C-peptide concentration during MMTT with high protein energy drink. "Dose" for time frame refers to intake of high protein energy drink.
| min*nmol/L | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC) | -32.357 ± 27.7184 | -25.171 ± 28.9450 | -21.682 ± 24.5787 | -34.393 ± 25.6837 | -16.909 ± 19.1278 |
| min*nmol/L | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Week 14 | -19.396 ± 23.7789 | -0.444 ± 18.8595 | 4.427 ± 33.2220 | -12.725 ± 20.2051 | 3.317 ± 21.1784 |
| Week 27 | -30.709 ± 21.2821 | -17.826 ± 21.0462 | 6.537 ± 56.1336 | -23.082 ± 22.3027 | -1.411 ± 26.8550 |
| Week 39 | -28.500 ± 37.6682 | -17.664 ± 26.1729 | -23.342 ± 21.6945 | -36.580 ± 20.7765 | -10.808 ± 20.0078 |
| Week 69 | -45.316 ± 27.1563 | -42.014 ± 15.7239 | -27.023 ± 28.6920 | -39.735 ± 23.3488 | -16.744 ± 21.8947 |
| Week 87 | -42.487 ± 31.9418 | -43.012 ± 23.2403 | -34.590 ± 21.6148 | -47.496 ± 23.7717 | -32.561 ± 20.0826 |
| Week 104 | -29.687 ± 25.5941 | -44.314 ± 28.0612 | -32.980 ± 18.2765 | -39.908 ± 26.4652 | -26.586 ± 20.6803 |
| percentage of change from baseline | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Week 14 | -0.68 ± 2.108 | -1.75 ± 2.543 | -1.16 ± 1.683 | -1.45 ± 1.812 | -2.64 ± 2.452 |
| Week 27 | -0.67 ± 1.953 | -1.38 ± 2.799 | -0.74 ± 2.263 | -0.89 ± 2.740 | -2.52 ± 2.439 |
| Week 39 | -0.58 ± 2.098 | -0.78 ± 3.043 | -0.40 ± 1.495 | -0.55 ± 2.798 | -1.52 ± 2.473 |
| Week 52 | -0.47 ± 1.383 | -0.55 ± 3.437 | -0.25 ± 1.399 | -0.51 ± 2.504 | -1.52 ± 2.805 |
| Week 69 | -0.01 ± 1.630 | -0.18 ± 2.529 | 0.09 ± 1.197 | -0.33 ± 2.532 | -1.37 ± 3.004 |
| Week 87 | -0.54 ± 1.310 | -0.38 ± 3.035 | 0.30 ± 2.147 | -0.26 ± 2.608 | -0.89 ± 3.011 |
| Week 104 | -0.76 ± 1.419 | -0.69 ± 2.490 | 0.28 ± 1.987 | -0.10 ± 2.890 | -1.36 ± 2.155 |
Severe hypoglycemia defined according the ADA Workgroup on Hypoglycemia definition, as follows: An event requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions.
| Participants | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| 1 episode | 1 | 2 | 0 | 0 | 1 |
| 2 episodes | 0 | 0 | 0 | 0 | 0 |
| 3 episodes | 0 | 0 | 1 | 0 | 0 |
| U/kg/day | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Week 2 | -0.146 ± 0.2044 | -0.141 ± 0.2143 | -0.205 ± 0.2194 | -0.274 ± 0.1416 | -0.158 ± 0.2828 |
| Week 4 | -0.147 ± 0.1405 | -0.264 ± 0.1456 | -0.201 ± 0.2058 | -0.220 ± 0.1744 | -0.150 ± 0.2788 |
| Week 14 | -0.239 ± 0.2301 | -0.305 ± 0.1406 | -0.092 ± 0.1442 | -0.239 ± 0.1430 | -0.118 ± 0.1114 |
| Week 27 | -0.040 ± 0.2313 | -0.033 ± 0.4310 | -0.090 ± 0.2117 | -0.138 ± 0.2321 | -0.135 ± 0.0607 |
| Week 39 | -0.040 ± 0.3222 | 0.146 ± 0.7900 | -0.089 ± 0.2099 | -0.158 ± 0.2552 | -0.150 ± 0.1100 |
| Week 52 | 0.226 ± 0.5861 | -0.037 ± 0.8720 | -0.055 ± 0.2180 | 0.214 ± 0.5898 | -0.320 ± 0.2906 |
| Week 69 | 0.192 ± 0.5491 | 0.213 ± 0.6097 | 0.142 ± 0.5981 | 0.016 ± 0.7005 | -0.011 ± 0.2858 |
| Week 87 | 0.517 ± 0 | 0.164 ± 0.5377 | 0.247 ± 0.6591 | 0.086 ± 0.5132 | -0.044 ± 0.4264 |
| Week 104 | 0.491 ± 0 | -0.168 ± 0.4650 | 0.307 ± 0.3772 | -0.015 ± 0.5626 | 0.303 ± 0 |
For each visit, the mean daily glucose levels were calculated over the previous 3-7 days prior to the study visit from blood glucose levels recorded daily prior to meals and bedtime.
| mmol/L | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Week 2 | 2.223 ± 3.6282 | 2.379 ± 2.7555 | 1.848 ± 1.1257 | 0.578 ± 1.6824 | 0.178 ± 1.5195 |
| Week 4 | 2.343 ± 2.3942 | 1.856 ± 2.4750 | 2.106 ± 1.3144 | 0.759 ± 1.0403 | -0.158 ± 1.4665 |
| Week 14 | 2.812 ± 2.5953 | 2.200 ± 2.1283 | 2.852 ± 3.0376 | 2.337 ± 3.9732 | -0.053 ± 1.4368 |
| Week 27 | 1.782 ± 1.7921 | 2.252 ± 2.8173 | 2.446 ± 3.2355 | 3.471 ± 3.1043 | 0.577 ± 2.1475 |
| Week 39 | 1.347 ± 2.0674 | 3.848 ± 2.2236 | 4.471 ± 2.7390 | 3.681 ± 4.0469 | 1.421 ± 2.1779 |
| Week 52 | 2.995 ± 1.6703 | 3.067 ± 2.9160 | 3.242 ± 3.1636 | 2.723 ± 4.3749 | 0.616 ± 2.1868 |
| Week 69 | 2.182 ± 1.3352 | 18.224 ± 41.1471 | 4.324 ± 4.4173 | 3.677 ± 3.7397 | 1.467 ± 4.2254 |
| Week 87 | 3.354 ± 2.9550 | 3.101 ± 2.3859 | 3.234 ± 2.1516 | 3.835 ± 3.6760 | 4.863 ± 2.5173 |
| Week 104 | 2.545 ± 0 | 1.867 ± 2.4532 | 2.390 ± 1.5429 | 2.283 ± 6.1064 | 2.431 ± 1.4519 |
Collected over All AEs occurring after subject consent through Week 52 were collected. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha1-PI 180 mg/kg/wk, 26 Weeks | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| 180 mg/kg/wk Alpha1-PI, 13 Weeks | 1/16 (6.3%) | 3/16 (18.8%) | 8/16 (50%) |
| 90 mg/kg/wk Alpha1-PI, 26 Weeks | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| 90 mg/kg/wk Alpha1-PI, 13 Weeks | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| Placebo | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Event | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Completed suicidePsychiatric disorders | 0/15 | 1/16 | 0/14 | 0/15 | 0/15 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/15 | 1/16 | 0/14 | 0/15 | 0/15 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/15 | 1/16 | 0/14 | 0/15 | 0/15 |
| Event | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/15 | 4/16 | 4/14 | 3/15 | 1/15 |
| HeadacheNervous system disorders | 3/15 | 3/16 | 4/14 | 1/15 | 1/15 |
| VomitingGastrointestinal disorders | 2/15 | 3/16 | 0/14 | 4/15 | 1/15 |
| NasopharyngitisInfections and infestations | 2/15 | 0/16 | 3/14 | 3/15 | 2/15 |
| ContusionInjury, poisoning and procedural complications | 0/15 | 0/16 | 3/14 | 0/15 | 1/15 |
| NauseaGastrointestinal disorders | 1/15 | 3/16 | 1/14 | 0/15 | 2/15 |
| GastroenteritisInfections and infestations | 0/15 | 2/16 | 2/14 | 0/15 | 0/15 |
| SinusitisInfections and infestations | 1/15 | 1/16 | 2/14 | 0/15 | 1/15 |
| ConstipationGastrointestinal disorders | 2/15 | 0/16 | 0/14 | 0/15 | 0/15 |
| InfluenzaInfections and infestations | 2/15 | 0/16 | 0/14 | 0/15 | 0/15 |
| Age, Customized(Participants) | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo | Total |
|---|---|---|---|---|---|---|
| 6 - 11 years | 2 | 3 | 3 | 3 | 2 | 13 |
| 12 - 17 years | 7 | 7 | 7 | 7 | 6 | 34 |
| 18 - 35 years | 6 | 6 | 5 | 5 | 7 | 29 |
| Sex: Female, Male(Participants) | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 8 | 9 | 4 | 4 | 31 |
| Male | 9 | 8 | 6 | 11 | 11 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 3 | 2 | 0 | 9 |
| Not Hispanic or Latino | 12 | 15 | 12 | 13 | 15 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Alpha1-PI 180 mg/kg/wk, 26 Weeks | 180 mg/kg/wk Alpha1-PI, 13 Weeks | 90 mg/kg/wk Alpha1-PI, 26 Weeks | 90 mg/kg/wk Alpha1-PI, 13 Weeks | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 2 | 0 | 3 |
| White | 14 | 14 | 15 | 13 | 15 | 71 |
| More than one race | 1 | 1 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2014, a primary completion of Jan 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin